Ensysce Biosciences Renews Collaboration With Quotient Sciences To Undertake The Study PF614-MPAR-102 To Examine And Evaluate The Full Commercial Dose Range Of The PF614-MPAR Drug Product
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences has renewed its collaboration with Quotient Sciences to conduct a study on the full commercial dose range of its breakthrough opioid product, PF614-MPAR, which aims to prevent overdose by shutting off opioid release when too many pills are ingested.
May 20, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences has renewed its collaboration with Quotient Sciences to study the full commercial dose range of its PF614-MPAR opioid product, which has been granted Breakthrough Therapy designation by the FDA.
The renewal of the collaboration and the FDA's Breakthrough Therapy designation for PF614-MPAR are positive developments for Ensysce Biosciences. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100